The Latest Breaking News from Novo Nordisk

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

There's an easy way to lower the cost of next-generation weight-loss drugs.

The company says its Vital Pursuit line, priced under $5, is high in protein and vitamins, addressing nutrient deficiencies that Ozempic and Wegovy users may have.

The compounded weight loss drug starts at $199 per month.

Microsoft is near a buy point with the market rally flashing green. It's one of five stocks to watch.

A recent clinical trial of Wegovy showed that 17 percent of patients on the drug left the trial because of side effects.

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market -…

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

The stock market rallied this week, with the Nasdaq regaining its 50-day on a semi-dovish Fed, a tame jobs report and a huge Apple buyback.